… developed a population pharmacokinetic model for midazolam in preterm neonates with a
… was it possible to develop a population pharmacokinetic model of this drug. Although the …

… In cohort 1, we obtained PK samples from infants receiving sildenafil as ordered per the local
… of sildenafil and performed PK sampling. We performed a population PK analysis and dose-…

… a few preterm neonates. Thus, we aimed to evaluate the population pharmacokinetics of …
size covering the entire age range of neonates and young infants and to establish evidence-…

… population PK in neonates and young infants (n = 128). It established an evidence-based
dosing scheme for this population using developmental PK… is optimal for population PK data …

… PBPK models combine demographic, genetic, physiological and pathological information
in adults with in vitro data on human drug metabolism and transport to predict population PK …

… pharmacokinetics of vancomycin vary among neonates, and we aimed to conduct population
pharmacokinetic … of vancomycin in Korean neonates. From a retrospective chart review, …

… a vancomycin population PK model for neonates and infants, … evaluation of vancomycin
PK in neonates and infants to our … in this study best predicts PK of our data compared to the …

… to develop a population pharmacokinetic (PK) model in … preterm neonates. By using an
optimal design approach, a prospective PK study was designed and implemented in 60 neonates …

… In summary, this report presents the first population pharmacokinetic model of PTX and its
principal metabolites and indicates that preterm infants' elimination capacity matures rapidly …

… models allows us to select the most adapted model for our population [27,28,29]. … population
pharmacokinetic models for piperacillin in neonates using clinical data collected for preterm …